KPC PHARMACEUTICALS,INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.53 CNY | +2.41% |
|
+5.33% | +8.01% |
| 04-19 | KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-17 | Kunyao Group Receives Clinical Trial Approval for FMF Drug | MT |
| Sales 2024 * | 8.58B 1.18B 94.81B | Sales 2025 * | 10.01B 1.38B 111B | Capitalization | 17.06B 2.35B 189B |
|---|---|---|---|---|---|
| Net income 2024 * | 601M 82.94M 6.64B | Net income 2025 * | 805M 111M 8.9B | EV / Sales 2024 * | 1.99 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.7 x |
| P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
21.2
x | Employees | 5,051 |
| Yield 2024 * |
1.35% | Yield 2025 * |
1.71% | Free-Float | 62.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.41% | ||
| 1 week | +5.33% | ||
| Current month | +4.74% | ||
| 1 month | +4.89% | ||
| 3 months | +22.85% | ||
| 6 months | +25.10% | ||
| Current year | +8.01% |
1 week
19.45
22.73
1 month
19.4522.73
Current year
17.2622.73
1 year
15.1826.09
3 years
8.0526.09
5 years
7.6426.09
10 years
5.9526.09
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Qiang Sun
DFI | Director of Finance/CFO | - | 02/01/23 |
Wei Yan
PSD | President | 53 | 18/01/23 |
Wen Sen Zhang
BRD | Director/Board Member | 52 | 31/08/97 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hua Wei Qiu
CHM | Chairman | 57 | 18/01/23 |
Jin Guo Xin
BRD | Director/Board Member | 62 | 31/10/09 |
Hui Zhou
BRD | Director/Board Member | 53 | 17/10/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 22.53 | +2.41% | 9,520,504 |
| 25/04/24 | 22 | +1.85% | 7,635,711 |
| 24/04/24 | 21.6 | +0.05% | 6,077,820 |
| 23/04/24 | 21.59 | +3.35% | 12,366,240 |
| 22/04/24 | 20.89 | -2.34% | 17,804,120 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
22.53
CNY
Average target price
25.01
CNY
Spread / Average Target
+11.01%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +8.01% | 2.35B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600422 Stock
